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Antitumor-analgesic peptide (AGAP) is a novel recombinant polypeptide. The primary
study showed that AGAP 1.0 mg/kg exhibited strong analgesic and antitumor effects.
The tail vein administration of AGAP potently reduced pain behaviors in mice induced
by intraplantar injection of formalin or intraperitoneal injection of acetic acid, without
affecting basal pain perception. To further assess the mechanisms of AGAP, the
effects of AGAP on sodium channels were assessed using the whole-cell patch clamp
recordings in dorsal root ganglia (DRG) neurons. The results showed that AGAP
(3–1000 nM) inhibited the sodium currents in small-diameter DRG neurons in a dose-
dependent manner. 1000 nM AGAP could inhibit the current density-voltage relationship
curve of sodium channels in a voltage-dependent manner and negatively shift the
activation curves. 1000 nM AGAP could reduce the tetrodotoxin-resistant (TTX-R)
sodium currents by 42.8% in small-diameter DRG neurons. Further analysis revealed
that AGAP potently inhibited NaV1.8 currents by 59.4%, and negatively shifted the
activation and inactivation kinetics. 1000 nM AGAP also reduced the NaV1.9 currents
by 33.7%, but had no significant effect on activation and inactivation kinetics. Thus,
our results demonstrated that submicromolar concentrations of AGAP inhibited TTX-
R sodium channel in rat small-diameter DRG neurons. It is concluded that these new
results may better explain, at least in part, the analgesic properties of this polypeptide.
Keywords: Voltage-gated sodium channels, Nav1.8, Nav1.9, pain, scorpion toxins
INTRODUCTION
Asian scorpion Buthus martensii Karsch, widely distributed in Mongolia, Korea, and China, has
been one of the indispensable materials used in Chinese traditional medicine for thousands
of years. In China, scorpions and their tissues have been extensively used for treatment of
analgesia, inflammatory, epilepsy, convulsion, anticancer, and so on. It is well known that
scorpion venom is complex mixture substances. It is a particularly rich source interacting
specifically with various ion channels in excitable cell membranes. Proteins from Scorpion
venom modes of action fall within two major categories: one is pore-blocking proteins which
block the movement of ions and the other alters the conformation of ion channel and also the
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statement of ion channel, such as open, closed or activation (Lai
et al., 2004).
Scorpion polypeptides have long chain and short chain
peptides. In 2003, the expression and purification of a novel
antitumor-analgesic peptide (AGAP) were reported in E. coli
(Herzog et al., 2001). BmK AGAP is a typical long-chain scorpion
toxin, which is composed of 66 amino acids cross-linked by four
disulfide bridges (Cys12–Cys63, Cys16–Cys36, Cys22–Cys46,
and Cys26-Cys48). The gene cloning (GenBank No. AF464898),
protein expression, and characterization of the encoding gene
of this peptide have been investigated (Liu et al., 2003). The
primary study showed that AGAP exhibited strong analgesic and
antitumor effects, but the analgesic mechanisms remain unclear
in VGSCs (Liu et al., 2003).
Voltage-gated sodium channels mediate the inward sodium
current and are critical for the initiation and propagation of
action potentials in excitable tissues, including the brain and
peripheral nerves (Payandeh et al., 2011). Nav1.3, Nav1.7, Nav1.8,
and Nav1.9 have been identified as possible targets for analgesics.
The development of chronic pain can be caused to peripheral
nerve injury which is related to hyperexcitability of sensory
neurons in DRG (Dib-Hajj et al., 2010; Ebersberger et al., 2011;
Djouhri et al., 2012). At least two types of sodium currents can
be recorded in small-diameter neuron of rat DRG (Caffrey et al.,
1992).
Previous reports have demonstrated that TTX-R is a unique
expression in the DRG neurons. Electrophysiological studies
in sodium channels also have confirmed that TTX-R sodium
currents may play a key role in setting the action potential
conduction in the unmyelinated C fibers which arise from
small DRG neurons (Jeftinija, 1994; Quasthoff et al., 1995).
TTX-R sodium channels, Nav1.8 and Nav1.9, both are strongly
implicated in the molecular mechanisms of nociception. In
contrast to fast activating and the rapidly inactivating TTX-S
channels, Nav1.8 channels exhibit ∼10-fold slower kinetics of
activation and inactivation, whereas Nav1.9-mediated currents
are persistent current with a more hyperpolarized voltage
dependence and ultraslow recovery from inactivation (Cummins
et al., 1999).
Many kinds of long-chain neurotoxins which modulate
sodium channels and calcium channels have been purified
from scorpion venom (Valdivia et al., 1992; Tan et al., 2001).
Our previous work has shown that AGAP potently inhibited
voltage gated calcium channels (VGCCs), especially high-voltage
activated calcium currents in rat DRG neurons (Liu et al.,
2014). Here, we examined whether AGAP could attenuate pain
behaviors in mice, and further assess the analgesic mechanisms
of AGAP, the present study was therefore designed to evaluate
the mechanisms of recombinant AGAP on the TTX-R sodium
channels in rat small-diameter DRG neurons.
MATERIALS AND METHODS
Animals
Adult 6 weeks male Sprague Dawley rats (160–220 g), and
Kunming mice (18–22 g) were used for the experiments. The
animals were housed at room temperature (23–26◦C) under a 12-
h light/dark cycle with ad libitum access to food and water. All
procedures were carried out in accordance with the Committee
Ethics of Animal Experiments of the Shenyang Pharmaceutical
University.
Behavioral Analysis
Acetic Acid-Induced Writhing Test
The male mice were treated with AGAP (0.25, 0.5, 1.0 mg/kg),
the reference antinociceptive drug morphine (2 mg/kg), or saline
as a negative control (n = 12 per group). The methods included
randomization and blinding in all vivo experiments. Acetic acid
(0.8% v/v, 10 ml/kg) was injected intraperitoneally, and the mice
were placed in a plastic cage. The abdominal writhes were defined
as extensions of the abdomen with outstretching of the hind
limbs. The intensity of pain was quantified by counting the
number of writhes occurring for 30 min after acetic acid injection.
Hot Plate Test
The hot plate was an electrically heated surface kept at a constant
temperature of 55.0 ± 0.5 ◦C. Female mice (n = 12 per group)
were placed on the heated surface, and the latency of pain
(jumping or licking of the paws) was recorded at 0, 30, 60, 90, and
120 min after drug administration, whereupon the reaction time
of 0 min is the start of the test. As previous researches indicated,
2 mg/kg morphine offered an ideal analgesic effect in the visceral
pain test (Meymandi and Keyhanfar, 2013), while in the hot plate
test, morphine couldn’t elicit significant analgesic effects at low
dosages until we raised the dosage to 5 mg/kg (Casarrubea et al.,
2012; Araújo et al., 2016). Morphine (5.0 mg/kg) was used as the
reference drug. Antinociceptive effects of AGAP and morphine
were compared in dose-response and time course experiments.
A cut-off time of 60 s was chosen to indicate complete analgesia
in order to avoid potential harmful effects. The latencies of pain
were recorded for each animal (Yamamoto et al., 2002).
Formalin Test
Formalin test was performed in male mice as Rosa et al. (2008)
described. Formalin solutions were prepared at 5% in saline
from a formalin stock and injected intraplantarly to the left hind
paw in a volume of 20 µl. AGAP at concentrations ranging
from 0.25 to 1.0 mg/kg was administered intravenously 20 min
before formalin injection. Morphine was administered at a dose
of 2 mg/kg (n= 12 per group). 30 min before formalin injection.
After the formalin injection, mice were immediately placed in
a clear, transparent box (11 cm × 11 cm × 16 cm) with a
mirror placed underneath at a 45◦ angle to view the animals’
paws completely. Then, mice were observed for 30 min after the
formalin injection, the times of licking or flinching the injected
hind paw from 0 to 5 min (first phase) and from 15 to 30 min
(second phase) was recorded as indicative of nociception.
Rotarod Test
Fine motor coordination and learning was assessed by using the
rotarod test (Munro, 2009). A control (saline) group and AGAP
group (treated 1.0 mg/kg; n = 10) were utilized. The fall-off
latency to the first fall was recorded.
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Immunohistochemistry
Rats were deeply anesthetized, and the L4−6 lumbar DRG
were removed quickly from the spinal cord, fixed with 4%
paraformaldehyde in 0.1 M phosphate buffer overnight at 4◦C.
After the tissues embedded by paraffin, a series of 5 µm
thick sections were cut for immunohistochemistry. Primary
antibodies targeting rat NaV1.8 (1:200; Alomone), NaV1.9 (1:200;
Alomone) and NF200 (1:200; Sigma) were performed for
immunohistochemistry overnight at 4◦C. After washing three
times with PBST, the sections were incubated with secondary
antibodies (1:100; sigma) for 1 h at 37◦C. Fluorescent images were
captured in an Olympus BX40 microscope (Olympus, Tokyo,
Japan).
Preparation of DRG Neurons
Primary Neuronal Cultures
L4−6 DRG tissue was removed from day 1–3 rat pups in Ca2+ and
Mg2+ free Hank’s, minced, and incubated for 15 min at 37◦C in
enzyme solutions containing trypsin and collagenase. The tissue
was triturated in culture medium containing 1:1 DMEM/F-12,
10% fetal calf serum, 5% horse serum, 1.5 mg/ml bovine serum
albumin, 100 U/ml penicillin and 0.1 mg/ml streptomycin and
plated (600–800 cells/mm2) on glass coverslips coated with Poly-
L-Lysine. The cells were maintained at 37◦C in a humidified 95%
air/5% CO2 incubator overnight, and studied with whole-cell
patch-clamp techniques after short-term culture (12–24 h).
DRG Neurons Acutely Isolated
Preparation of DRG neurons was established as described
previously (Yu et al., 2011). Briefly, SD rats weighing about
150 g (6 weeks of age) were deeply anesthetized, L4−6
DRG neurons were dissociated using enzyme digestion as
previously described with slight modifications. The cells were
then triturated and plated onto acid-washed coverslips that had
been coated previously with 0.01% poly-L-lysine. Media consisted
of Dulbecco’s Modified Eagle Medium/Ham’s F12 medium
(DMEM/F12) supplemented with 10% (v/v) heat-inactivated
horse serum and 10% (v/v) fetal bovine serum. Cell densities
at plating were 800–1000 cells/ml. The cells were maintained at
37◦C in a humidified 95% air/5% CO2 incubator and were studied
between 2–12 h after removal from the animal.
Electrophysiological Recordings
Voltage-gated sodium currents of L4−6 DRG neurons were
recorded in the whole-cell configuration of the patch clamp
method (Li et al., 2010). During experiments, membrane
potential and currents were recorded from small-diameter DRG
neurons using the whole-cell patch clamp technique under visual
control with Nikon TE2000-U inverted microscope. Patch-clamp
electrodes were pulled with a P-97 puller, and had a resistance of
3–5 M. The experiment of whole-cell patch clamp was carried
out using an AxoPatch 200B amplifier (Axon Instruments, Foster
City, CA, USA); all signals were low pass filtered at 1.5 kHz
and the sampling rate was 10 kHz, then sampled data were
stored digitally on a computer for further analysis. The pipette
solution contained (in mM): 100 CsCl, 30 CsF, 8 NaCl, 2.4 CaCl2,
1 MgCl2, 5 EGTA, 4 Na2ATP, 10 HEPES, 0.4 GTP (pH 7.3,
Osmolarity is 290–300 mOsm). The bathing solution contained
(in mM): 100 choline chloride, 40 NaCl, 3 KCl, 2.5CaCl2, 1
MgCl2, 10 HEPES, 10 glucose, 0.005 LaCl3 (pH 7.4, Osmolarity
is 290–300 mOsm), supplemented with 1 µM TTX when the
currents of TTX-R, NaV1.8 and NaV1.9 channel were recorded.
The pipette offset was used to back the liquid junction potential
to zero before patch formation. Capacitive transients and series
resistances were compensated electronically by 70–80%. After
seal formation and membrane rupturing, the cells were allowed
to stabilize for 3 min before rupturing the pulse protocols. All
experiments were carried out at room temperature (23± 2◦C).
Reagents
CsCl, CsF, TTX, LaCl3, HEPES, Poly-L-lysine, EGTA, Na2ATP,
and GTP were purchased from Sigma-Aldrich, whereas
DMEM/F12, horse serum, and fetal bovine serum were from
Gibco. Penicillin and streptomycin were purchased from
Invitrogen. AGAP was synthesized by the laboratory of Dr.
Zhang Jinghai.
Stock solutions of AGAP were prepared in physiological saline
and diluted in assay buffer immediately before use. AGAP was
dissolved in the bath solution. Throughout the experiment, bath
or AGAP solutions were delivered to the DRG neurons via a
fast gravity-driven perfusion system. The doses of AGAP were
determined by the preliminary experiments in vivo or vitro
experiment.
Data Analysis
The Dose-Response Curves
The dose-response curves for AGAP was determined from
a curve fit of the Hill equation to the data points: f =
1
/{
1+ (IC50/ [AGAP])nH}, where f is the fractional current
block at the test potential, nH is the Hill coefficient, and [AGAP]
is the concentration of AGAP. The inhibition effect calculated as
the mean reduction of maximum peak amplitude.
Establish Voltage-Dependent Steady-State Activation
Curves
The voltage dependence of activation was determined
using standard protocols. The conductance G (V) was
calculated according to G = I/ (V − VNa), where VNa
is the reversal potential, V is the test pulse potential
and I is the current amplitude. Normalized peak
conductance was fitted by the following Boltzmann equation:
G
/
Gmax = 1
/ {
1+ exp [(V1/2 − V) /k]}, where Gmax is the
maximum conductance, V1/2 is the membrane potential of
half-maximal activation and k is the slope factor.
Establish Voltage-Dependent Steady-State
Inactivation Curves
Steady state inactivation curves were determined
with a Boltzmann fit of the data using:
I
/
Imax = 1
/ {
1+ exp [(V − V1/2) /k]}, where I is the current
amplitude, Imax is the maximal current amplitude, V is the
prepulse, V1/2 is the prepulse voltage at which the current
amplitude is half maximum, and k is the slope factor.
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The voltage-clamp data were digitized and analyzed
using pClamp 10.0 software (Axon Instruments). Multiple
comparisons were evaluated by one-way ANOVA followed by
Tukey’s test, two-way ANOVA or repeated-measure two-way
ANOVA followed by Bonferroni test. When only two groups
were compared, an unpaired t-test was used. Data were expressed
as mean ± standard error of mean (SEM). P < 0.05 indicated
statistically significant differences.
RESULTS
Effects of AGAP on Acetic Acid-Induced
Abdominal Writhing Visceral Pain
We first tested the effects of intravenously administered
AGAP to reduce pain-related behaviors after intraperitoneal
administration of 0.8% acetic acid. As shown in Figure 1,
intraperitoneal administration of acetic acid induced significant
abdominal writhing in mice. When mice were pretreated with
AGAP, we observed significant dose-dependent effect of AGAP
(0.5–1.0 mg/kg) on acetic acid-induced writhing relative to
vehicle-treated mice. In order to compare the antinociceptive
effect of AGAP, a group of mice were administered with
morphine. The results showed that 2.0 mg/kg morphine also
significantly reduced the total number of writhes. Inhibition
ratio of writhes is 69.8 and 60.2% after administration of AGAP
(1.0 mg/kg) and morphine (2.0 mg/kg), respectively (P < 0.001
and P < 0.01, respectively, n= 12 in each group).
Effects of AGAP on the Hot
Plate-Induced Nociception
To complement and extend our in vivo studies, the
antinociceptive effects of AGAP were studied in the hot
FIGURE 1 | Effect of Antitumor-analgesic peptide (AGAP) on acetic
acid-induced writhing test in mice. After intravenously injection of AGAP,
mice received an intraperitoneal injection of 0.8% acetic acid, and abdominal
writhes were counted for 30 min. AGAP dose-dependently inhibited the total
number of writhes. ∗∗p < 0.01, ∗∗∗p < 0.001 compared with control group. It
is no significance of comparison between morphine and 1.0 mg/kg AGAP
(p > 0.05). Data are shown as the mean ± SEM (n = 12 per group). P values
are from one-way ANOVA followed by Tukey’s test.
plate test in mice. AGAP was injected into the caudal vein
of mice, the physiological saline was a control, and the
pain latency was recorded. On the hot plate assay, AGAP
(0.5–1.0 mg/kg) significantly increased the response latency
compared with the control group (Figure 2). The observed
pharmacological action was similar to morphine (5.0 mg/kg).
The latency did not return to baseline within 120 min for
test.
Effects of AGAP on Formalin-Induced
Nociception
To further determine whether AGAP induces analgesia effect,
we examined paw licking and flinching responses to intraplantar
injection of 5% formalin into the hind paw after an injection
of AGAP. Formalin concentrations >0.5% induces a biphasic
response in rodents (Shields et al., 2010). AGAP resulted in a
significant dose-dependent suppression of pain behaviors relative
to vehicle-injected mice in both characteristic first (0–5 min)
and second (15–30 min) phases of the behavioral response to
formalin (Figure 3). The inhibition rate of 1.0 mg/kg AGAP
were 78.2 and 81.5% for the first phase and second phase of
formalin response, respectively (P< 0.001, n= 12 in each group).
The results demonstrated that the suppressive effects of AGAP
were similar efficient on both phases. In order to compare the
antinociceptive potency of AGAP, another group of mice ware
injected with morphine. Similar to AGAP, morphine significantly
inhibited pain responses of both phases after formalin injection.
The analgesic effect of 1.0 mg/kg AGAP was stronger than
2.0 mg/kg morphine (Figure 3, P < 0.01, n = 12 in each
group).
Rotarod Test
There were no significant differences between control group and
1.0 mg/kg AGAP. The fall-off latencies ranged from 108.64± 3.98
to 101.51 ± 4.12 after administration of 1000 nM AGAP
(p > 0.05, P values are from unpaired t-test, n = 10). The
results indicated that AGAP treatments didn’t impair motor
function.
Expression Profiles of NaV1.8 and NaV1.9
in DRG Neurons
In mammals, acute pain is transmitted to the CNS mainly
by two VGSCs, TTX-S Nav1.7 and TTX-R Nav1.8, which are
expressed in small-diameter DRG neurons (Dib-Hajj et al.,
2010). Nociceptors also express Nav1.9, a second TTX-R sodium
current involved in diabetic neuropathy and inflammatory pain
(Cummins et al., 1999; Ebersberger et al., 2011). We compared
NaV1.8 and NaV1.9 localizations by double immunofluorescent
labeling with NF200, a marker of large- and medium-sized
neurons (Figure 4). Our results showed that NaV1.8 mainly
expressed in small- and medium-sized DRG neurons that rarely
contained NF200, whereas NaV1.9 selectively expressed in small-
sized DRG neurons that completely did not contain NF200.
This finding is similar to preliminary reported results (Yu et al.,
2011; Li et al., 2015). Therefore, DRG neurons with diameters of
15–25µm (small-sized) were selected for continued experiments.
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FIGURE 2 | Reaction time of animals in hot plate test: 0, 30, 60, 90, and 120 min after treatment of AGAP and morphine. Animals were pretreated with
vehicle, morphine (5 mg/kg), AGAP (0.25, 0.5, and 1.0 mg/kg) prior to the tests at 55◦C. Each column represents the mean with X ± SEM. for twelve mice in each
group. The symbols denote the significance levels: ∗∗p < 0.01, ∗∗∗p < 0.001 compared with control group. Morphine and 1.0 mg/kg AGAP were not statistical
difference (p > 0.05). Data are shown as the mean ± SEM (n = 12 per group). P values are from two-way ANOVA followed by Bonferroni test.
FIGURE 3 | Effect of AGAP against formalin induced licking and flinching in mice. AGAP at concentrations ranging from 0.25 to 1.0 mg/kg was administered
intravenously 20 min before formalin injection. Morphine was administered at a dose of 2 mg/kg i.p. 30 min before formalin injection. The total time spent on licking
and flinching of the affected paw was measured in the first (0–5 min) phase and the second (15–30 min) phase after intraplantar injection of formalin. AGAP
dose-dependently attenuated the formalin-induced licking and flinching responses in both two phases. ###p < 0.001 compared with control group; ∗p < 0.05,
∗∗∗p < 0.001 compared with formalin group. Data are shown as the mean ± SEM (n = 12 per group). P values are from two-way ANOVA followed by Bonferroni test.
Effects of AGAP on Voltage-Dependent
Sodium Currents in Rat Amall-Diameter
DRG Neurons
In electrophysiological testing experiment, voltage-dependent
calcium and potassium channels were pharmacologically
blocked. Sodium currents were maximally activated by a test
pulse at −10 and 0 mV, and peak amplitude at these potential
were −5262 ± 928 and −4658 ± 1016 pA in cultured small
diameter DRG neurons (Figure 5A, n = 15) and acutely isolated
small DRG neurons (Figure 5B, n = 19), respectively. AGAP
(1000 nM) inhibited the sodium currents in cultured and acutely
isolated small DRG neurons, as shown in Figure 5C (P < 0.05,
n = 19 and n = 15, respectively). 5 min after addition of
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FIGURE 4 | Expression profiles of NaV1.8 and NaV1.9 in DRG neurons (×200). Double immunofluorescent labeling of L4−6 DRG neurons by anti-NaV1.8 (red)
and anti-NF200 (green) or anti-NaV1.9 (red) and anti-NF200 (green) antibodies.
FIGURE 5 | AGAP inhibits voltage-gated sodium current in primary
cultured and acutely isolated small-diameter neurons of rat. (A,B)
Following the blockade of calcium and potassium channels, depolarizing
voltage commands from −80 to +50 mV from a holding potential of −90 mV
elicited fast inward currents. The inward current responses were significantly
reduced after the application of AGAP (1000 nM) in cultured and acutely
isolated small-diameter DRG neurons. (C) The percentage inhibition for INa
was 46.9 ± 8.7 and 41.1 ± 6.2% in cultured and acutely isolated
small-diameter DRG neurons, respectively (∗p < 0.05, P values are from
unpaired t-test, n = 15 and n = 19, respectively).
1000 nM AGAP, the rate of inhibition for INa was 46.9 ± 8.7
and 41.1 ± 6.2% in cultured and acutely isolated small-diameter
DRG neurons, respectively. The inhibition effect calculated as
the mean reduction of maximum peak amplitude. The results
showed that the pharmacological action of AGAP was similar
in primary cultured and acutely isolated small DRG neurons.
The acutely isolated small diameter DRG neurons were used to
accomplish the following experiments.
Effects of AGAP on Current
Density–Voltage Relationship and
Concentration – Dependent Inhibition of
AGAP on Sodium Currents
Current density-voltage relationships of sodium currents in
small-diameter DRG neurons were shown in Figure 6A.
AGAP modified the voltage threshold of the activation or the
potential at which the inward current reached maximal values.
The concentration-responsiveness of AGAP was investigated
by measuring current density-voltage relations under different
concentrations of AGAP (Figure 6B). AGAP (30–1000 nM)
reduced the sodium currents in all the DRG neurons. The process
that AGAP reduced the inward sodium currents was dose-
dependent and the minimal effective concentration was obtained
with 30 nM AGAP (P < 0.05, n = 8). The concentration-
responsiveness in acutely isolated rat small-diameter DRG
neurons was shown in Figure 6C.
Then, we examined the effect of AGAP on activation kinetics
of the sodium currents. DRG cells were held at −120 mV,
then, the membrane was depolarized from -90 to +60 mV in
increments of 10 mV. Boltzmann functions constructed from
the average values for V1/2 and k were shown superimposed
on the data points with V1/2 = −19.1 ± 0.3 mV in control
and V1/2 = −25.0 ± 0.7 mV with 1000 nM AGAP in small-
diameter DRG neurons (Figure 6D, P < 0.05, n = 7). AGAP
shifted the voltage dependency of activation in rat small-diameter
DRG neurons. Slope factors were 3.2 ± 0.3 and 2.7 ± 0.3 mV
before and after administration of 1000 nM AGAP. Slope
factors were not significantly different (Figure 6D, P > 0.05,
n= 7).
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FIGURE 6 | Effect of AGAP on NaV channel currents in small-diameter DRG neurons. (A) Current density-voltage relationship obtained by plotting current
density as a function of test potential under control conditions and after application of 1000 nM AGAP. (n = 7). (B,C) The graph shows the dose–response
relationship of the effect of AGAP in acutely isolated small-diameter DRG neurons (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, P values are from unpaired t-test.
n = 8–13). (D) Effect of AGAP on steady-state activation kinetics of NaV channels. Data points were fitted with the Boltzmann equation. V1/2 was −19.1 ± 0.3 mV
under control conditions and −25.0 ± 0.7 mV in the presence 1000 nM of AGAP (P < 0.05, P values are from unpaired t-test. n = 7); slope factors were 3.2 ± 0.3
and 2.7 ± 0.3 mV, respectively.
Effects of AGAP on TTX-R Sodium
Currents in Rat Small-Diameter DRG
Neurons
The TTX-S sodium currents of the rat small-diameter DRG
neurons could be abolished by 1 µM TTX, indicating that the
sodium channels expressing in small-diameter DRG neurons
have TTX-S and TTX-R sodium channels (Figure 7A). Our
current density-voltage relationship of TTX-R sodium currents
in DRG neurons was shown in Figure 7B. These inward TTX-R
sodium currents were maximally activated by a test pulse at −10
and 0 mV (n= 6).
In a first series of experiments, calcium, potassium and TTX-S
sodium currents were pharmacologically blocked by extracellular
application of 4-AP, TEA, La3+ and TTX as well as by the
addition of Cs+ in the recording electrode. Effects of AGAP on
TTX-R sodium currents were investigated in DRG neurons after
complete inhibition of TTX-S INa currents using 1.0 µM TTX.
The results showed that AGAP 1000 nM reduced TTX-R INa peak
amplitude by 42.8% (Figures 7C,D, P < 0.01, n = 9). The peak
amplitudes were−1070.1± 407.9 and−636.2± 253.5 nA before
and after the application of 1000 nM AGAP.
Effects of AGAP on NaV1.8 currents were investigated in
acutely isolated rat DRG neurons lacking detectable NaV1.9.
Figure 7C shows representative NaV1.8 current traces. Currents
were elicited by steps to membrance potential between −90 and
+60 mV from a holding potential of −120 mV, at which most
channels are in the resting-state. AGAP had obvious inhibitory
effects on NaV1.8 current amplitudes. 1000 nM of AGAP reduced
NaV1.8 current amplitudes by 59.4% (Figures 7E,F, P < 0.01,
n = 5). Representative NaV1.9 current traces are shown in
Figure 7G in control condition and in the presence of 1000 nM
AGAP. Currents were elicited by depolarizing steps to −35 mV
from a Vh of −100 mV. AGAP (1000 nM) inhibited NaV1.9
current amplitudes at 33.7% (Figure 7H, P < 0.05, n = 9). Mean
value of Nav1.8 and Nav1.9 sodium currents reversal potential are
+55 and+63 mV, respectively.
Effects of AGAP on Steady-State
Activation and Inactivation Kinetics of
NaV1.8 Currents
Voltage-dependent steady-state activation and inactivation
properties of sodium channels contribute to membrane
excitability. Therefore, some kinetic properties of the NaV1.8
and NaV1.9 channels were investigated in small-diameter
DRG neurons. NaV1.8 currents were evoked to −50 mV over
the course of 500 ms, followed by the application of voltage
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FIGURE 7 | Effect of AGAP on the TTX-R sodium currents in small-diameter DRG neurons. (A) Representative traces showing the depression of 1000 nM
TTX on NaV channel currents in rat small diameter DRG neuron. (B) Current density-voltage relationship obtained by plotting current density as a function of test
potential under control conditions and after application of 1000 nM TTX (n = 6). (C) Representative traces showing the depression of AGAP on TTX-R currents in a
neuron. (D) 1000 nM AGAP inhibited TTX-R currents by 42.8% (P < 0.05, P values are from unpaired t-test, n = 9). (E) Representative traces showing the
depression of AGAP on NaV1.8 currents in a neuron. (F) At a concentration of 1000 nM, AGAP potently inhibited NaV1.8, decreasing current amplitude by 59.4%
(P < 0.01, P values are from unpaired t-test. n = 5). (G) Representative traces showing the depression of AGAP on NaV1.9 currents in a neuron. (H) 1000 nM AGAP
reduced NaV1.9 currents by 33.7% (P < 0.05, P values are from unpaired t-test. n = 9).
steps ranging from −50 to +50 mV in increments of 10 mV
(Figure 8A). The normalized peak conductance was plotted
against voltage and fitted with the Boltzmann equation. AGAP
shifted negatively the V1/2 of activation by 4.6 mV from
−13.0 ± 0.2 mV in control conditions to −17.6 ± 0.4 mV
(Figure 8B, P < 0.05, n = 5). Slope factors were 2.8 ± 0.1 and
4.2 ± 0.3 mV before and after application of 1000 nM AGAP
(Figure 8B, P < 0.05, n= 5).
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FIGURE 8 | Effect of AGAP on the dynamic function of NaV1.8 channels. (A,B) AGAP shifts the conductance-voltage relationship to more negative potentials.
(A) Representative steady-state activation of NaV1.8 under the control conditions and in the presence of 1000 nM AGAP. (B) Normalized activation kinetics
determined before and after the application of AGAP. V1/2 was −13.0 ± 0.2 mV in control conditions and −17.6 ± 0.4 mV in the presence of 1000 nM AGAP
(P < 0.05, n = 5). Slope factors were 2.8 ± 0.1 and 4.2 ± 0.3 mV, respectively (P < 0.05, n = 5). P values are from unpaired t-test. (C,D) AGAP had no effect on the
voltage-dependence of steady-state inactivation. (C) Representative steady-state inactivation of NaV1.8 under the control conditions and in the presence of
1000 nM AGAP. (D) Normalized peak currents were plotted against membrane potential and Boltzmann equation was used to fit data. V1/2 was −25.0 ± 0.3 mV in
control conditions and −25.4 ± 0.6 mV in the presence of 1000 nM AGAP. Slope factors were −5.5 ± 0.3 and −6.0 ± 0.5 mV, respectively (P > 0.05, P values are
from unpaired t-test. n = 5).
To study the properties of steady-state inactivation of NaV1.8
channels, a series of prepulses from −70 to 0 mV were followed
by a testing pulse of 0 mV. AGAP (1000 nM) slightly shifted
the inactivation curves of Nav1.8 but there were no significant
differences (Figure 8C). V1/2 values were −24.9 ± 0.6 and
−28.4 ± 0.6 mV in the absence or presence of AGAP. Slope
factors were−6.1± 0.5 and−7.4± 0.5 mV, respectively. Steady-
state inactivations and slope factors were not statistically different
in the absence or presence of AGAP (Figure 8D, P > 0.05,
n= 5).
Effects of AGAP on Steady-State
Activation and Inactivation Kinetics of
NaV1.9 Currents
Another TTX-R sodium channel expressed in DRG neurons is
NaV1.9. NaV1.9 generates a low-threshold sodium current with
slow rates of activation and inactivation, giving rise to a persistent
current component. Fluoride-containing patch pipette solution
was used to record NaV1.9 currents. Activation properties were
studied by applying voltage steps from −80 to −35 mV from a
holding potential of −100 mV (Figure 9A). AGAP (1000 nM)
had no significant effects on the voltage-dependence of the
activation curves. V1/2 for activation was −38.4 ± 1.5 mV in
control conditions and −38.2 ± 3.7 mV in the presence of
1000 nM AGAP. Slope factors were 6.1 ± 0.5 and 7.8 ± 1.1 mV,
respectively (Figure 9B, P > 0.05, n= 7).
To study the properties of steady-state inactivation of
NaV1.9 channels, a series of prepulses from −120 to 0 mV
were followed by a testing pulse of −50 mV (Figure 9C).
AGAP (1000 nM) had no significant effects on Nav1.9 channel
inactivation (Figure 9D). The values of the parameters of V1/2
and k were −67.9 ± 2.2 and −11.0 ± 1.8 mV under control
conditions and −69.6 ± 2.5 and −12.5 ± 2.0 mV in the
presence of 1000 nM AGAP, respectively (Figure 9D, P > 0.05,
n= 6).
DISCUSSION
Recent evidences that sodium channel activities and
expressions altered in peripheral neurons can contribute to
the pathophysiology of peripheral neuropathy (Lai et al., 2002;
Amir et al., 2006; Dib-Hajj et al., 2010). Scorpion venom has
been proved to be a rich source of ion channel regulators. Here,
we examined the effect of AGAP, a long-chain scorpion peptides,
to anti-nociception by studying behavioral phenotypes of mice.
Subsequently, the effect of AGAP on VGSCs was detected in
rat small-diameter DRG neurons by whole-cell patch clamp
technique.
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FIGURE 9 | Effect of AGAP on the dynamic function of NaV1.9 channels. 1000 nM AGAP did not significantly affect the voltage-dependence of channel
activation or steady-state inactivation. (A,B) Effect of AGAP on steady-state activation kinetics of NaV1.9 currents. V1/2 was −38.4 ± 1.5 mV in control conditions
and −38.2 ± 3.7 mV in the presence of 1000 nM AGAP. Slope factors were 6.1 ± 0.5 and 7.8 ± 1.1 mV, respectively (n = 7). (C,D) Steady-state inactivated of
Nav1.9 in the absence and presence of AGAP. V1/2 for inactivation was −67.9 ± 2.2 mV in control conditions and −69.6 ± 2.5 mV in the presence of 1000 nM
AGAP. Slope factors were −11.0 ± 1.8 and −12.5 ± 2.0 mV, respectively (P > 0.05, P values are from unpaired t-test. n = 6).
The results showed that AGAP significantly inhibited the
response of writhing in a dose-dependent manner on acetic-acid-
induced writhing. We further investigated the antinociceptive
role of AGAP in an acute inflammatory pain condition
induced by intraplantar injection of formalin. Our results
confirmed that AGAP had a significant analgesic activity in
both the first and second phases. Besides, AGAP also showed
a significant increase in latency to the thermal stimuli in
hot plate test, suggests a better antinociceptive activity of
AGAP.
Some small peptide inhibitors of N-type channel have shown
effect in the treatment of pain. Such as the ω-conotoxin
MVIIA has been isolated from venom of Conus magus has
been used to treat intractable pain as an analgesic drug (Staats
et al., 2004; Stix, 2005). The possible reason is that these
inhibitors block the synaptic transmission of signal pathways
of pain to the central nervous system (Feng et al., 2001;
Yarotskyy and Elmslie, 2009). Most of the long-chain scorpion
peptides are the modulators of sodium and calcium channels
(Possani et al., 2000; Li et al., 2004). The previous study has
shown that AGAP potently inhibited voltage-gated calcium
channels in the small diameter DRG neurons (Liu et al.,
2014). We have demonstrated that AGAP decreases the HVA
calcium channels, especially N-type calcium currents, while
N-type calcium channels are expressed in presynaptic and may
have more influence on EPSC/EPSP than other calcium type
(Tsuzuki et al., 2004). Voltage-gated L-type calcium channels
help to maintain longer-lasting depolarizations to reduce firing
threshold and regulate repetitive firing as well as shaping
regenerative action potentials. Our results strongly suggest that
the modulation of VGCCs is a possible mechanism for reduction
of neuronal excitability.
These results suggest that antinociceptive effect of AGAP
may be ascribed to its specific modulation of voltage-gated
ion channels of sensory neurons. Comparing the important
role of voltage-gated calcium channels, VGSCs are present in
excitable membranes and play a fundamental role in action
potentials generation (Payandeh et al., 2011). VGSCs are the
important targets for analgesic drugs (Sleeper et al., 2000;
Maingret et al., 2008). Next, to determine the effect whether
AGAP modulates sodium channels underlying the generation
of pain. We found AGAP decreased the sodium currents in
a concentration-dependent manner. To our studies, this is the
first experimental evidence demonstrating that AGAP is an ion
channel regulator with many different actions on a variety of
neuronal ion channels including HVA, LVA calcium channels and
TTX-R sodium channels.
Nav1.8 and Nav1.9 contain a structural common motif of
TTX-R sodium channel subtype that both of them are remarkably
expressed in peripheral sensory neurons (Dib-Hajj et al., 2010;
Yu et al., 2011), and are thought to play an important role
in ectopic discharge in neuronal bodies and axons following
peripheral nerve injury (Akopian et al., 1996; Dib-Hajj et al.,
1998; Kral et al., 1998; Berta et al., 2008); these properties
have identified them as potential molecular targets for analgesic
drugs. Both TTX-R subtypes, Nav1.8 and Nav1.9, have been
Frontiers in Pharmacology | www.frontiersin.org 10 December 2016 | Volume 7 | Article 496
fphar-07-00496 December 16, 2016 Time: 12:43 # 11
Li et al. AGAP, Pain Relief through Sodium Channels
implicated in nociception, including neuronal pain signaling
triggered by inflammation (Lai et al., 2002, 2004), and the
Nav1.8 is essential for neuropathic pain at low temperatures
(Zimmermann et al., 2007). The result confirms that AGAP
might attenuate pain by blocking TTX-R channels in small-
diameter DRG neurons. Our further results showed that 1000 nM
AGAP reduced the Nav1.8 and Nav1.9 currents, the inhibitory
percentage of Nav1.8 and Nav1.9 currents were 59.4 ± 5.1 and
33.7 ± 6.6%, respectively. The results suggested that the effect
of AGAP on Nav1.8 channels was stronger than that of Nav1.9
channels.
The voltage-gated Nav1.8 channel has been demonstrated
having a significantly higher inactivation threshold, slower
inactivation kinetics, and a faster recovery from inactivation
comparing with TTX-S Na+ channels (Cummins and Waxman,
1997), this suggests that Nav1.8 channel is a major contributor
to the action potential upstroke in C-type small DRG neurons
(Renganathan et al., 2001). The Nav1.8 expression has been
reported to increase in the setting of persistent inflammatory pain
(Gaida et al., 2005; Villarreal et al., 2005). Some studies suggest
that Nav1.8 mutations contribute to pain in some peripheral
neuropathies (Faber et al., 2012). Our results showed that AGAP
suppresses Nav1.8 currents, suggesting the upstroke of the action
potential is blocked by AGAP in sensitive neurons. We predicted
that AGAP can reduce Nav1.8 currents, decrease membrane
excitability and block AP propagation in nociceptive sensory
neurons as well.
AGAP significantly shifted the steady-state activation curves
of Nav1.8 currents to more negative potentials, and the
inactivation curves of Nav1.8 currents were also shifted to
negative potentials. The shift of steady-state activation may speed
up the activation process of Nav1.8 channel. At the same time
AGAP may also expedite the inactivation process, this is, the time
to entry into activation is shortened.
Nav1.8 is important in the development and/or maintenance
of nerve injury-induced pain, several Nav1.8-selective inhibitors
have been reported to be analgesic in several neuropathic (Jarvis
et al., 2007), and it has also been suggested that Nav1.8 might
be a potential target of AGAP in inflammatory and neuropathic
antinociceptive mechanism.
The Nav1.9 channel is preferentially expressed in nociceptive
DRGs and trigeminal nerve neurons (Amaya et al., 2000;
Eriksson et al., 2005; Fang et al., 2006), and is known to
contribute to the persistent thermosensitive and spontaneous
pain by peripheral administration of inflammatory mediators
(Crill, 1996; Coste et al., 2004; Priest et al., 2005). The present
results showed that AGAP efficiently inhibited Nav1.9 channels
in small-diameter DRG neurons in a concentration-dependent
manner. The decrease of Nav1.9 currents was associated with
subthreshold regenerative depolarization, active hyperpolarizing
responses, oscillatory bursting discharges, plateau potentials and
bistable membranes behaviors (Maingret et al., 2008). Our results
suggested that following the inhibition of AGAP in Nav1.9
channels, the currents reduction of Nav1.9 and the subsequent
loss of this depolarizing influence would cause a hyperpolarizing
shift in resting potential, elevating the threshold for initiating
action potentials.
Nav1.9 channels play a major role in mediating inflammatory
rather than neuropathic pain, and contribute to the
hyperexcitability of nociceptors observed during inflammatory
pain (Priest et al., 2005; Amaya et al., 2006; Ostman et al.,
2008). Cummins and Waxman (1997) suggested that, following
axotomy, downregulation of Nav1.9 and the subsequent loss
of this depolarizing influence would cause a hyperpolarizing
shift in resting potential and remove resting inactivation on
TTX-S Na+ channels, thereby producing hyperexcitability.
A link between the Nav1.9-associated persistent current and
the pain sensation was demonstrated in neurons from Nav1.9
knockout mice that lack persistent Na+ current and have greatly
reduced inflammatory hyperalgesia (Priest et al., 2005; Amaya
et al., 2006). AGAP reduced the Nav1.9 current, but activation or
steady-state inactivation of Nav1.9 was not significantly changed
in small-diameter DRG neurons. The results suggest that the
AGAP may decrease the effect of Nav1.9 about depolarization
of the resting membrane potential, lowering the threshold level
for initiating subsequent action potentials (Cummins et al., 1999;
Herzog et al., 2001; Baker et al., 2003). AGAP might attenuate
inflammatory pain by blocking Nav1.9 sodium channels in
nociceptors.
Some researches indicted that TTX-R sodium channels might
not be related to the conduction of potential, but have an import
role in the action potential generation. The currents reduced
by AGAP of Nav1.8 and Nav1.9 channels may also reduce the
generation of action potentials. Neurotoxins alter ion channel
functions by binding to different sites (Ekberg et al., 2008).
Scorpion toxins were individed into α- and β-scorpion toxins.
The α-scorpion toxins, which bind to site 3 on VGSCs, slow
inactivation processes, and the β-scorpion toxins, which binds
to site 4 on VGSC, enhance the activation process. Scorpion
depressant β-toxins are considered as analgesic peptides (Chen
et al., 2006). According to electrophysiological characteristics of
AGAP compared to those of other scorpion toxins, AGAP can be
classified as a β-neurotoxin.
In summary, our results have shown that AGAP had a
significant anti-nociceptive activity in an animal model of
pain. AGAP as potential analgesics is still in the preclinical
stage. Although AGAP could modulate the function of calcium
channels and TTX-R sodium channels in DRG neurons, AGAP-
induced modulation on other ion channels still need to be further
investigated. But according to our results, AGAP modulated
currents of calcium channels and TTX-R sodium currents in
small-diameter DRG neurons, which probably partly contributes
to the mechanism of the decreased neuron excitability, blocking
neuronal signaling and inducing analgesia.
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